Rns17 Feb 2020 10:35
Angle PLC Data demonstrates key advantages of Parsortix
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 1262D
Angle PLC
17 February 2020
For immediate release 17 February 2020
ANGLE plc ("the Company")
LEADING KOL PUBLISHES ANALYTICAL AND CLINICAL DATA DEMONSTRATING KEY ADVANTAGES OF PARSORTIX SYSTEM
Hamburg-Eppendorf developed validated standardised Parsortix protocols for use in future clinical trials
Parsortix harvested cells allow for "robust amplification of single cell DNA at excellent quality for subsequent molecular analysis"
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that University Medical Centre Hamburg-Eppendorf has published results of work undertaken to assess the analytical and clinical performance of Parsortix in multiple metastatic cancer types with the main emphasis on metastatic breast cancer.
The work was completed as part of the pan-European CANCER-ID consortium funded by the European Innovative Medicine Initiative (IMI), which aims to standardise protocols and validate innovative circulating tumour cell (CTC) detection approaches for future clinical trials.
The results demonstrated the capability of the Parsortix system to work with multiple different cancer types, using multiple blood preservative tube types, and importantly capturing the full range of CTCs, not just epithelial CTCs.
The researchers demonstrated that the CTCs harvested by the Parsortix system were suitable for "robust amplification of single cell DNA at excellent quality for subsequent molecular analysis". Even in metastatic NSCLC (non small cell lung cancer) and gastrointestinal cancer, which are known to be problematic for CTC enrichment, the Parsortix workflow harvested CTCs in 46% of patients notwithstanding treatment and disease condition. The researchers stated in the publication that they had established optimised enrichment protocols, utilising Parsortix, which ensured robust performance.
The research has been published as a peer-reviewed publication in the journal Cancers and may be accessed via https://angleplc.com/library/publications/ .
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"This publication adds to the body of evidence supporting the use of Parsortix in standard practice as part of personalised cancer care. Hamburg-Eppendorf is considered a leader in Europe in the field and their positive evaluation of Parsortix is an important element in supporting the potential use of Parsortix in future pharma services clinical trials."
As previously announced, f ollowing the Q-Submission meeting in January with FDA, ANGLE is now progressing a full De Novo FDA Submission with the prospect of FDA clearance in Q3 CY20, albeit the outcome and timing of the FDA regulatory decision is entirely dependent on the FDA's review and response to the Company's submission.
For further information ANGLE:
ANGLE plc
Sign In
Follow the stocks
